Mouse Anti-Trx-2 Monoclonal Antibody, Unconjugated, Clone 71G4 from Santa Cruz Biotechnology, Inc.
Description:Trx-2 (71G4)...LIC Duet™ Trx•Tag™ Ek Adaptor from Novagen
Description:The LIC Duet™ Trx•Tag™ Ek Adaptor encodes a T7 promoter, E. coli</i...FliTrx Panning Kit from Invitrogen
Description:The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....Tracker Datamatrix TRxD from Micronic BV
Description:Tracker Datamatrix TRxD reads any 1D and 2D barcodes within 0.5 seconds....METRx X-Tube Retraction System
Description:The METRx Microdiscectomy System incorporates specially designed metal tubes that allow surgeons to access a surgical area in a minimally invasive manner. These tubes, called dilators, vary in diameter size from 5.3 mm to 20.8 mm. The METRx Microdiscectomy System dilators are inserted sequentially - one around the other - through the muscle to gradually separate, or split, the muscle fibers, crea...TherMatrx® Dose Optimized Thermotherapy™
Description:TherMatrx® Dose Optimized Thermotherapy™ is an advanced transurethral microwave thermotherapy system designed for in-office treatment of benign prostate hyperplasia (BPH). TherMatrx is the most widely used in-office BPH thermotherapy treatment in the United States. Unlike surgical solutions for BPH, TherMatrx does not require cutting, heavy sedation or hospitalization. A single TherMatr...CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
LOS ANGELES--(BUSINESS WIRE)--Jun 27, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayannounced promising data from the six-month, open-label extensionof its completed Phase IIa clinical trial with arimoclomol in ALSvolunteers. While the clinical trial was not placebo-controlled,arimoclomol at a 1...CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation(NASDAQ:CYTR), a biopharmaceutical company engaged in thedevelopment and commercialization of human therapeutics, todayreported safety and tolerability results from its previouslyannounced double-blind, placebo-controlled, rising multiple doseclinical trial in healthy volunteers with its drug candidatearimoclomol. CytRx believes...Adventrx Announces Positive Data From Multidrug Therapy With CoFactor
Data Presented at American Association for Cancer Research AnnualMeeting SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- ADVENTRXPharmaceuticals, Inc. , a biopharmaceutical research anddevelopment company focused on commercializing proprietary productcandidates for the treatment of cancer and infectious diseases,today announced positive results from preclinical studies using amultidr...